Effect of rosuvastatin trreatment on cholesterol efflux from human mocrophages

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F11%3A00002498" target="_blank" >RIV/00023001:_____/11:00002498 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of rosuvastatin trreatment on cholesterol efflux from human mocrophages

Popis výsledku v původním jazyce

OBJECTIVES: One of the positive effects of rosuvastatin is an increase in HDL cholesterol (HDL-C). An increase in HDL-C is considered as one of the positive effects of this type of statin, although it does not necessarily correspond to the actual reversecholesterol transport (RCT) rate. We analyzed the influence of statin induced changes in HDL-C on cholesterol efflux (CHE), the key step affecting the RCT. DESIGN: Fourteen subjects (7 men, age: 50.9 ? 8.4 years and 7 women, age: 59.7 ? 10.6 years) withmixed dyslipidemia received 20 mg of rosuvastatin daily for 3 months. Before the initiation of statin therapy and at the end of the study period, the CHE from 14C cholesterol-labeled macrophages was determined in addition to parameters related to lipidmetabolism. CHE was calculated as the percentage of radioactivity released from the macrophages into the media containing 5% of the examined plasma. RESULTS: The rosuvastatin administration resulted in significant reductions of total chol

Název v anglickém jazyce

Effect of rosuvastatin trreatment on cholesterol efflux from human mocrophages

Popis výsledku anglicky

OBJECTIVES: One of the positive effects of rosuvastatin is an increase in HDL cholesterol (HDL-C). An increase in HDL-C is considered as one of the positive effects of this type of statin, although it does not necessarily correspond to the actual reversecholesterol transport (RCT) rate. We analyzed the influence of statin induced changes in HDL-C on cholesterol efflux (CHE), the key step affecting the RCT. DESIGN: Fourteen subjects (7 men, age: 50.9 ? 8.4 years and 7 women, age: 59.7 ? 10.6 years) withmixed dyslipidemia received 20 mg of rosuvastatin daily for 3 months. Before the initiation of statin therapy and at the end of the study period, the CHE from 14C cholesterol-labeled macrophages was determined in addition to parameters related to lipidmetabolism. CHE was calculated as the percentage of radioactivity released from the macrophages into the media containing 5% of the examined plasma. RESULTS: The rosuvastatin administration resulted in significant reductions of total chol

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neuroendocrinology letters

ISSN

0172-780X

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

—

Stát vydavatele periodika

SE - Švédské království

Počet stran výsledku

5

Strana od-do

24-28

Kód UT WoS článku

000300544200007

EID výsledku v databázi Scopus

—